Rapid Onset and Sustained Efficacy (ROSE) study: Results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass

Osteoporosis International

Volumn 23, Issue 2, 2012, Pages 625-633

  Hadji, P ^a   Gamerdinger, D ^b   Spieler, W ^c   Kann, P H ^a   Loeffler, H ^d   Articus, K ^d   Moricke R ^e   Ziller, V ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Orthopedic Practice ^*  (Germany)

^c Research Center for Osteology and Rheumatology   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e Endocrinologic Practice   (Germany)

Author keywords

Bisphosphonates; Bone loss; Bone markers; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRON HEXAL; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE MASS; BONE METABOLISM; BONE PAIN; BONE TURNOVER; CHILL; CONNECTIVE TISSUE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EAR DISEASE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; INJECTION SITE REACTION; INJURY; INNER EAR DISEASE; INTOXICATION; LIMB PAIN; MAJOR CLINICAL STUDY; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NERVOUS SYTEM DISEASE; OPEN STUDY; OSTEOARTHRITIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SKIN DISEASE; THORAX DISEASE; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VASCULAR DISEASE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 84857370164     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1583-4     Document Type: Article

References (28)

1. G Owens R Jackson M Lewiecki 2007 An integrated approach: bisphosphonate management for the treatment of osteoporosis Am J Manag Care 13 S290 S308 18095779
2. JA Kanis N Burlet C Cooper PD Delmas JY Reginster F Borgstrom R Rizzoli 2008 European guidance for the diagnosis and management of osteoporosis in post menopausal women Osteoporos Int 19 399 428 18266020 10.1007/s00198-008-0560-z 1:STN:280:DC%2BD1c3itFekuw%3D%3D
3. C Cooper 1999 Epidemiology of osteoporosis Osteoporos Int 9 Suppl 2 S2 S8 10525719 10.1007/PL00004156
4. HK Kamel MS Hussain S Tariq HM Perry JE Morley 2000 Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture Am J Med 109 326 328 10996585 10.1016/S0002-9343(00)00457-5 1:STN:280: DC%2BD3M%2Fitlakuw%3D%3D
5. JY Reginster N Burlet 2006 Osteoporosis: a still increasing prevalence Bone 38 S4 S9 16455317 10.1016/j.bone.2005.11.024
6. ZA Cole EM Dennison C Cooper 2008 Osteoporosis epidemiology update Curr Rheumatol Rep 10 92 96 18460262 10.1007/s11926-008-0017-6
7. B Clarke 2008 Normal bone anatomy and physiology Clin J Am Soc Nephrol 3 Suppl 3 S131 S139 18988698 10.2215/CJN.04151206 1:CAS:528:DC%2BD1cXhsVemtrbO
8. National Osteoporosis Foundation (2008). Clinician's guide to prevention and treatment of osteoporosis. Available at: http://www.nof.org/professionals/ NOF-Clinicians-Guide.pdf. Accessed on: 1 March 2010
9. HG Ahlborg O Johnell BE Nilsson S Jeppsson G Rannevik MK Karlsson 2001 Bone loss in relation to menopause: a prospective study during 16 years Bone 28 327 331 11248665 10.1016/S8756-3282(00)00451-8 1:STN:280:DC%2BD3M3lvFymsA%3D%3D
10. SL Bonnick L Shulman 2006 Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119 S25 S31 16563938 10.1016/j.amjmed.2005.12.020
11. FR Singer DR Eyre 2008 Using biochemical markers of bone turnover in clinical practice Cleve Clin J Med 75 739 750 18939390 10.3949/ccjm.75.10.739
12. JP Brown C Albert BA Nassar JD Adachi D Cole KS Davison KC Dooley A Don-Wauchope P Douville DA Hanley SA Jamal R Josse S Kaiser J Krahn R Krause R Kremer R Lepage E Letendre S Morin DS Ooi A Papaioaonnou LG Ste-Marie 2009 Bone turnover markers in the management of postmenopausal osteoporosis Clin Biochem 42 929 942 19362543 10.1016/j.clinbiochem.2009.04.001 1:CAS:528: DC%2BD1MXnt1emt74%3D
13. P Bergmann J-J Body S Boonen Y Boutsen JP Devogelaer S Goemaere JM Kaufman JY Reginster V Gangji 2009 Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian bone Club Int J Clin Pract 63 19 26 19125989 10.1111/j.1742-1241.2008.01911.x 1:CAS:528:DC%2BC3cXktFGnsLc%3D
14. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 6 12817758 10.1359/jbmr.2003.18. 6.1051 1:CAS:528:DC%2BD3sXkslOhsb0%3D
15. P Hadji H Minne M Pfeifer P Bourgeois P Fardellone A Licata V Devas D Masanauskaite E Barrett-Connor 2008 Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized crossover study (BALTO II) Joint Bone Spine 75 303 310 18069036 10.1016/j.jbspin.2007.07.011 1:CAS:528:DC%2BD1cXnsFWkt7w%3D
16. A Höer C Seidlitz H Gothe G Schiffhorst M Olson P Hadji B Häussler 2009 Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis Patient Prefer Adherence 3 25 30 19936142
17. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D
18. KW Lyles CS Colón-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 17878149 10.1056/NEJMoa074941 1:CAS:528:DC%2BD2sXht1Kit7nN
19. R Bartl S Gotte P Hadji T Hammerschmidt 2006 Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment Dtsch Med Wochenschr 131 1257 1262 16755420 10.1055/s-2006-946559 1:STN:280: DC%2BD28zptVOhsA%3D%3D
20. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 1 31 41 1244564 10.1159/000180580 1:STN:280: DyaE28%2FnsF2isw%3D%3D
21. K Saag R Lindsay A Kriegman A Kriegman E Beamer W Zhou 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 1238 1243 17347063 10.1016/j.bone.2007.01.016 1:CAS:528: DC%2BD2sXktF2nsrg%3D
22. O Demontiero G Duque 2009 Once-yearly zoledronic acid in hip fracture prevention Clin Interv Aging 4 153 164 19503777 1:CAS:528:DC%2BD1MXhsVOgu7vJ
23. RR Recker PD Delmas J Halse IR Reid S Boonen PA García-Hernandez J Supronik EM Lewiecki L Ochoa P Miller H Hu P Mesenbrink F Hartl J Gasser EF Eriksen 2008 Effects of intravenous zoledronic acid once yearly on bone remodelling and bone structure J Bone Miner Res 23 6 16 17892374 10.1359/jbmr.070906 1:CAS:528:DC%2BD1cXhtVCmt7c%3D
24. T Mashiba S Mori DB Burr S Komatsubara Y Cao T Manabe H Norimatsu 2005 The effects of suppressed bone remodelling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib J Bone Miner Metab 23 Supp 36 42 15984412 10.1007/BF03026321 1:CAS:528: DC%2BD2MXmvVynur0%3D
25. AS Neviaser JM Lane BA Lenart F Edobor-Osula DG Lorich 2008 Low-energy femoral shaft fractures associated with alendronate use J Orthop Trauma 22 346 350 18448990 10.1097/BOT.0b013e318172841c
26. EB Kwek SK Goh JS Koh MA Png TS Howe 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39 224 231 18222447 10.1016/j.injury.2007.08.036
27. DM Black AV Schwart KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings 2006 Effects of continuing or stopping alendronate after 5 years of treatment-The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938 17190893 10.1001/jama.296.24.2927 1:CAS:528:DC%2BD2sXnvVGh
28. DM Black MP Kelly HK Genant L Palermo R Eastell C Bucci-Rechtweg J Cauley PC Leung S Boonen A Santora A de Papp DC Bauer The Fracture Intervention Trial and HORIZON Pivotal Fracture Trial Steering Committees 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N Engl J Med 362 1761 71 20335571 10.1056/NEJMoa1001086 1:CAS:528:DC%2BC3cXmtVSrsr4%3D